

Stakeholder Engagement – Section 172 Statement

At MSD, one of the top five biopharmaceutical companies in the world, we ‘Invent For Life’. Our sole purpose is to save and improve lives by being at the forefront of pioneering science. We want to change the world but know we can’t do it alone. We bring our science to the patient, and in doing so, our business touches the lives of many people through our partnerships and collaborations. This means we operate in a demanding scientific and complex regulatory environment, and in doing so, engage with a number of stakeholders.

What we do and how we do it matters. Our values are our core: putting patients first, respect for people, ethics and integrity and innovation and scientific excellence. Our Code of Conduct enables our employees to operate with the highest levels of integrity at every level throughout our organisation.

The table below identifies our key stakeholders and how we have engaged with them throughout 2019.

Stakeholder Group	Interests	Business and Director Engagement
	<p><i>What are their key interests? What issues and factors are important to them?</i></p>	<p><i>How did the business and its’ directors engage with this stakeholder in 2019?</i></p>
Regulatory Bodies	<ul style="list-style-type: none"> ➤ Compliance with Medicines and Controlled Drug Regulations ➤ Reviewing, evaluating, and approving applications for Investigational Medical Products (IMP) and Non-IMP clinical trials ➤ Sets standards for interactions between industry and health professionals ➤ Protect and promote the interests of patients and the public in health and social care ➤ Compliance with financial reporting regulations 	<ul style="list-style-type: none"> ➤ Timely submission of high quality and accurate documentation ➤ Direct, open and transparent engagement on inspections, audits and enquiries (internal and external) ➤ Through industry associations, industry association boards, forums, conferences and meetings
Patients	<ul style="list-style-type: none"> ➤ Promote the patient voice in order to improve patients' experience of healthcare ➤ Access to safe and efficacious medicine ➤ Minimal burden associated with clinical trial participation 	<ul style="list-style-type: none"> ➤ Engaged directly (meetings, membership, social media and events), as well as indirectly (through industry associations) to ensure the development of any solution, treatment, or digital strategy is patient-centric ➤ Indirect engagement through clinical trial participation and data collection.
Government and Payers	<ul style="list-style-type: none"> ➤ Set the policies, rules, regulations and operating environment for life sciences, health and medicines ➤ Responsible for providing evidence-based guidance on health and social care ➤ Ensure accountability of the health and care system to Parliament and the taxpayer ➤ Support the NHS to deliver high quality, safe and sustainable care. 	<ul style="list-style-type: none"> ➤ Directly through meetings and written submissions to inquiries and consultations. Indirectly through industry associations ➤ Enable our product for the benefit of the patient through HTA and Regulatory approvals and supply to the markets in line with the contracts with government bodies ➤ Indirect engagement via industry (ABPI) association boards

Stakeholder Group	Interests	Business and Director Engagement
	<p><i>What are their key interests? What issues and factors are important to them?</i></p>	<p><i>How did the business and its' directors engage with this stakeholder in 2019?</i></p>
<p>Health Care Practitioners (HCP's) and Health Care Organisations (HCO's)</p>	<ul style="list-style-type: none"> ➤ Accurate and up-to-date Medical Information on licensed products ➤ Collaboration, Joint Working and Sharing of Information ➤ Health and high quality care for all ➤ Advancing science by providing modern medicine to patients to address unmet medical needs 	<ul style="list-style-type: none"> ➤ Provision of Medical Information in response to individual, unsolicited enquiries ➤ Engagement as consultants to address company knowledge gaps via advisory boards or as speakers for medical education activities ➤ Provision of medical education via resources and meetings, including congress attendance ➤ Collaboration on Joint Working Projects and proactive Medical Educational Goods and Services (MEGS). ➤ Promotion of MSD Medicines
<p>Our People</p>	<ul style="list-style-type: none"> ➤ Values, standards and Ways of Working (WOW) ➤ Competitive and fair compensation, benefits, flexible working, training and development opportunities ➤ Diversity and Inclusion ➤ Health and Safety 	<ul style="list-style-type: none"> ➤ Regular Town Halls ➤ Intranet and email weekly round up communications across all UK sites ➤ Internal and external surveys ➤ Employee Representative Committees ➤ Office of Ethics - safe to speak up environment
<p>Suppliers</p>	<ul style="list-style-type: none"> ➤ Understanding of MSD's strategy and how the supplier can best create value through innovative and new opportunities ➤ Creating a collaborative and trusting environment between the supplier and MSD ➤ That MSD acts ethically and have open and transparent processes ➤ Economic inclusion that supports supplier diversity 	<ul style="list-style-type: none"> ➤ Partner/sponsor with organisations that promote supplier diversity ➤ Engage collaboratively at a regional and global level to leverage enterprise-wide supplier relationships ➤ Work closely with the business to identify current and future needs and identify suppliers that can service these requirements ➤ Supplier Relationship management - manage and develop relationships that meet mutual long-term business objectives